OVC.1
NCT02446600
OVC.1
A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status:
Closed to Accrual
III
Phase
2nd+
Line of Therapy
Relapsed / Recurrent / Refractory
Disease Stage
Biomarker(s)
BRCA1/2
Investigational
Product
Olaparib + Cediranib Maleate
Treatment Arms
o Active Comparator: Arm I (platinum-based chemotherapy)
o Experimental: Arm II (olaparib)
o Experimental: Arm III (olaparib, cediranib maleate)